Arthritis Research UK Fellow
Lucy Norling graduated in Applied and Human Biology (BSc) from Aston University, Birmingham in 2003, followed by a Masters in Research and PhD at the William Harvey Research Institute, Queen Mary University of London in 2008. Dr. Norling was then awarded 3 year Arthritis Research UK Foundation Fellowship and spent two years training at Harvard Medical School, Boston, with the mentorship of Professor Charles Serhan. In 2012 Dr Norling attained a 5 year Arthritis Research UK Career Development Fellowship to further her studies on the role of resolvins in inflammatory arthritis.
Summary of Research
Bioactive lipid mediators in resolution of Inflammation
My interests are investigating the bioactions of novel lipid mediators that are derived from omega-3 fatty acids, in particular the DHA-derived Resolvins. These endogenous mediators have anti-inflammatory and pro-resolving properties and may explain the protective effects seen in RA patients taking fish oil supplements. My research focuses on the mechanisms by which Resolvins limit leukocyte recruitment to inflammatory sites, a hallmark of the inflammatory response. With Arthritis Research UK, I spent two years training at Harvard Medical School, Boston, with the mentorship of Professor Charles N. Serhan, who pioneered this field. My future research plans are to investigate whether dysfunctional pathways in the generation of these lipid mediators exist in chronic inflammatory pathologies such as RA.
Members of the Group
PhD students: Rachael Wright; Patrícia Souza